We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
22 hedge funds and large institutions have $7.52M invested in CASI Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
10% more funds holding
Funds holding: 20 → 22 (+2)
9.97% more ownership
Funds ownership: 9.87% → 19.84% (+10%)
8% less capital invested
Capital invested by funds: $8.14M → $7.52M (-$616K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Holders
22
Holders Change
+2
Holders Change %
+10%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$328K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$636 |
| 3 |
Morgan Stanley
New York
|
+$237 |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$24 |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$135K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$87.8K |
| 3 |
WSC
Wellington Shields & Co
New York
|
-$61.7K |
| 4 |
WSCM
Wellington Shields Capital Management
New York
|
-$16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16K |
